Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii + keaprazole-based quadruple therapy for H. pylori in elderly chronic gastritis
ChiCTR2600126920Phase 4Not yet recruiting
- Sponsor
- Anning City First People's Hospital
- Start
- Jun 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of saccharomyces boulardii in Helicobacter pylori infection and chronic gastritis (2 arms), sponsored by Anning City First People's Hospital. Primary endpoint: Helicobacter pylori eradication rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
Helicobacter pylori infectionchronic gastritis
Beyond the preview
Go deeper on ChiCTR2600126920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126920.